Maria de Fatima Dias Gaui

Prof. Dr. Maria de Fatima Dias Gaui

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
MGMaria de Fatima Dias Gaui
Maria de Fatima Dias Gaui
GAGilberto Amorim
Gilberto Amorim
RARoberto Alfonso Arcuri
Roberto Alfonso Arcuri
GPGuilherme Pereira
Guilherme Pereira
DMDenise Moreira
Denise Moreira
NSNelson Spector
Nelson Spector
Objective: According to data from Brazil's National Cancer Institute nearly 30% of the new patients who present with breast cancer have locally advanced disease. These patients are inoperable and tumor reduction is usually attempted with chemotherapy. First-line anthracyclin-based neoadjuvant chemotherapy is often effective; however, about 30% of the patients fail and to date there is no established second-line treatment. We have studied the concomitant use of radiation therapy and capecitabine in this setting, to determine the toxicity and efficacy of this regimen as a second-line neoadjuvant treatment. Patients and Methods: Twenty-eight patients with inoperable locally advanced breast cancer refractory to first-line anthracycline based treatment were enrolled between January 2003 and May 2004. Patients received radiation therapy (50 cGy) and concomitant capecitabine (850 mg/m2) twice daily for 14 days every 3 weeks. Results: This treatment rendered 23 of the 28 patients (82%) operable. The 5 remaining patients did not undergo surgery because of disease progression. The median clinical tumor size decreased from 80 cm2 to 49 cm2. Microscopic residual disease was observed in 3 patients (13%) and another patient achieved a complete pathologic response. The median number of involved lymph nodes was 2 and treatment was well tolerated with no grade 3 or 4 events. Conclusion: Our data indicate that second-line neoadjuvant treatment with radiation therapy and capecitabine is feasible, well tolerated, and effective in patients with locally advanced breast cancer refractory to primary anthracycline-based treatment. These results suggest that a randomized study should be done to compare radiotherapy alone to capecitabine combined with radiotherapy.

1 January 2026 in Cancer Research Communications
Verified
Journal Article
Open access
AMAna Carolina Monteiro
Ana Carolina Monteiro
DGDiego D. Garcia
Diego D. Garcia
AFAna Paula A. Fontão
Ana Paula A. Fontão
BRBárbara Du Rocher
Bárbara Du Rocher
MMMaria E. Globa Masset
Maria E. Globa Masset
ABAdriana Bonomo
Adriana Bonomo
Bone metastases represent a common and devastating complication of breast cancer; however, the immune determinants of skeletal colonization, particularly the role of adaptive lymphocyte subsets, have only recently been elucidated. In this study, we identified a nonclassical regulatory role of CD19+ B cells in the modulation of bone remodeling and breast cancer metastatic progression. Using murine models of metastatic 4T1 and nonmetastatic 67NR mammary tumors, we show that 67NR-bearing mice exhibit increased trabecular bone mass, associated with osteoprotegerin (OPG) secretion by CD19+IgD+IgM+CD138− B cells. Functional assays demonstrated that 67NR-primed B cells suppressed bone resorption in vitro and counteracted 4T1-specific T cell–mediated osteolytic activity in vivo. Adoptive transfer of 67NR-primed CD19+ B cells into 4T1-bearing immunocompetent or immunodeficient hosts preserved bone architecture, reduced RANKL production, inhibited metastases, and limited tumor growth. These effects are T cell–independent at the effector phase but require T cell-licensing for the acquisition of the OPG-producing phenotype. Silencing OPG abrogated this protective function. Mechanistically, B cells must be transferred during the early stages of tumor progression to retain their therapeutic potential. Molecular analyses supported the enrichment of RANKL+CD4+ T cells in tumors and lymph nodes, whereas OPG+ B cells were restricted to tumors. Transcriptomic data from The Cancer Genome Atlas further support the prognostic relevance of these immune phenotypes. In a retrospective human cohort, high RANKL+ lymphocyte infiltration in primary tumors correlated with bone metastases, whereas OPG+ infiltration predominated in bone metastasis–free cases. These findings uncover a B cell–driven axis that restrains osteolysis and tumor progression. Significance: This study identifies opposing RANKL+ T cell and OPG-producing B cell immune phenotypes that shape bone metastasis risk in breast cancer. By revealing how these adaptive lymphocyte subsets influence osteolysis and skeletal colonization, our findings define prognostic immune signatures with potential utility for early risk stratification and clinical decision-making.

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
ESEmília Rosaria Carvalho dos Santos
Emília Rosaria Carvalho dos Santos
MSMarcelo Soares da Mota e Silva
Marcelo Soares da Mota e Silva
NCNathalie Henriques Silva Canedo
Nathalie Henriques Silva Canedo
MGMaria de Fatima Dias Gaui
Maria de Fatima Dias Gaui
ÁBÁlvaro Luiz Vieira Lubambo de Britto
Álvaro Luiz Vieira Lubambo de Britto
GNGuilherme Pinto Bravo Neto
Guilherme Pinto Bravo Neto
This study aimed to determine the frequencies of Epstein-Barr virus, types 1 and 2 infection, and 30 bp del-latent membrane protein 1 viral polymorphism in gastric adenocarcinomas, as well as to investigate the association between Epstein-Barr virus infection and tumor location, type, and the patient's sex.

1 January 2022 in Brazilian Journal of Oncology
Verified
Journal Article
Open access
DTDiego de Araujo Toloi
Diego de Araujo Toloi
LLLuciana Castro Garcia Landeiro
Luciana Castro Garcia Landeiro
RGRodolfo Gadia
Rodolfo Gadia
CCCristiane de Lacerda Gonçalves Chaves
Cristiane de Lacerda Gonçalves Chaves
DFDaniel Neves Forte
Daniel Neves Forte
CMClarissa Mathias
Clarissa Mathias
Spirituality is a dynamic and an intrinsic aspect of humanity and is usually intense in cancer for patients, families, and health care teams. Evidence on spirituality, health, and healing have increased over the last decades. This consensus is for those involved in cancer patient care, with concepts and possible strategies for addressing spirituality, with discussion on the relevance, impact, and challenges of spirituality care. The purpose and intent of the consensus are to highlight the need for spirituality inclusion in the complex and delicate trajectory of cancer patients.

1 January 2021 in Mastology
Verified
Journal Article
Open access
LALuís Claudio Belo Amendola
Luís Claudio Belo Amendola
MGMaria de Fatima Dias Gaui
Maria de Fatima Dias Gaui
ACAna Helena Pereira Correia Carneiro
Ana Helena Pereira Correia Carneiro
NCNathalie Henriques Silva Canedo
Nathalie Henriques Silva Canedo
Introduction: The objective of this study is to describe the profile of patients from a public institution, submitted to neoadjuvant chemotherapy (NACT), comparing the verified pathological response with literature data. Methods: Observational retrospective cohort study on breast cancer patients diagnosed between September 2001 and October 2018 and treated with NACT at Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), located in Rio de Janeiro, Brazil. The adopted neoadjuvant chemotherapy regimen was based on anthracycline and docetaxel. Results: A total of 133 patients were evaluated. The average age in this group was 54 years (28-86), 49 women (37%) were under 50 years old. The following distribution by molecular subtype was observed: overexpression or amplification of the human epidermal growth factor receptor 2 (HER2+) (13 women, 26.6%), Luminal (19 women, 38.8%), and Triple-negative (TN) (17 women, 34.6%). The HER2+ and TN subtypes had a higher incidence of cases between 40-49 years and 50-59 years. As for the initial staging, 34% were IIIA; 26%, IIB; and 19%, IIIB. Only one patient did not undergo surgery after NACT, 33 (24.8%) underwent conservative surgery, and 99 patients (74.4%) underwent mastectomy. Regarding the axillary approach, 41 (31%) underwent sentinel lymph node biopsy and 88 (66%) had an indication for lymphadenectomy. In the anatomopathological evaluation of the surgery, 12 (9.1%) patients obtained a pathologic complete response (pCR) and 113 (84.9%), partial or no response to chemotherapy. Conclusion: This research enabled the identification of clinicopathologic characteristics and outcome of patients who received neoadjuvant chemotherapy in a public university service. The predominance of advanced tumors was observed, stressing the need for public health policies for the screening of breast cancer as well as the guarantee of timely treatment for diagnosed cases. The data somewhat reflect the difficulty that the public sector encounters to carry out the most appropriate treatment. The authors expect that this article, by analyzing the profile and the adopted treatment in real-life cases and in a public university institution, can contribute to the improvement of breast cancer treatment in Brazil.

1 April 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
DSDaniele Assad Suzuki
Daniele Assad Suzuki
MGMaria de Fatima Dias Gaui
Maria de Fatima Dias Gaui
DRDaniela Dornelles Rosa
Daniela Dornelles Rosa
KMKarime Kalil Machado
Karime Kalil Machado
FMFernanda Cesar Moura
Fernanda Cesar Moura
CMClarissa Maria de Cerqueira Mathias
Clarissa Maria de Cerqueira Mathias
PURPOSE: There are no available data concerning gender equity and workplace mistreatment within the field of oncology in Brazil. The Brazilian Society of Clinical Oncology (Sociedade Brasileira de Oncologia Clínica [SBOC]) performed a survey study to present and discuss this subject and gain insights into strategies that would mitigate gender inequities. MATERIALS AND METHODS: A 24-question survey in Portuguese, assessing demographics, professional context, achievements, workplace mistreatment, parenthood, and gender balance in the workplace, was developed and administered by the SBOC Women's Leadership Committee. SBOC members were invited to participate by e-mail. RESULTS: Among the 2,125 SBOC members, 146 women (72%) and 56 men (28%) participated in the survey. Approximately 87.5% of men versus 65.5% of women believed that they had equal rights ( P < .002) at their workplace. Chiefs of oncology departments were more often men than women (30.4% v 13.7%, P < .006). Furthermore, 60.8% of men versus 85.1% of women ( P = .0003) believed that a specific workplace guideline regarding gender equity should exist. Only 29.5% of women versus 98.2% of men ( P < .0001) believed that they did not experience gender discrimination throughout their careers. Approximately 50% of women versus 21% of men reported experiencing moral harassment at work ( P = .0002), whereas 24% of women and 7% of men reported sexual harassment ( P = .005). Multivariable logistic regression confirmed the significant results of univariable analysis when adjusted for age group and holding a department chief position. CONCLUSION: Our data show an alarming level of sexual and moral harassment and gender inequity experienced by SBOC members, highlighting the urgent need for programs to address these situations.